Table 1 Patient demographics
From: The impact of increasing dose on overall survival in prostate cancer
Dose | 68–69.99 Gy | 70–71.99 Gy | 72–73.99 Gy | 74–75.99 Gy | 76–77.99 Gy | 78–79.99 Gy | ≥80 Gy | |
|---|---|---|---|---|---|---|---|---|
Number of patients | 4,565 | 3,956 | 4,594 | 3,604 | 2,007 | 628 | 674 | |
Age (Years) | Median | 72 | 71 | 71 | 70 | 71 | 71 | 71 |
Interquartile Range | [67, 76] | [66, 75] | [66, 75] | [65, 75] | [65, 75] | [66, 76] | [66, 75] | |
Race | White | 85 % | 81 % | 84 % | 82 % | 85 % | 82 % | 86 % |
Black | 12 % | 16 % | 14 % | 15 % | 12 % | 16 % | 12 % | |
Asian/American Indian | 1 % | 1 % | 1 % | 1 % | 1 % | 1 % | 1 % | |
Unknown | 2 % | 2 % | 1 % | 2 % | 2 % | 1 % | 1 % | |
Marital status | Single | 18 % | 17 % | 20 % | 20 % | 22 % | 21 % | 23 % |
Married | 74 % | 74 % | 72 % | 67 % | 69 % | 68 % | 72 % | |
Unknown | 8 % | 9 % | 8 % | 13 % | 9 % | 11 % | 5 % | |
T stage | T1 | 44 % | 45 % | 57 % | 57 % | 59 % | 53 % | 52 % |
T2 | 47 % | 45 % | 37 % | 37 % | 36 % | 37 % | 34 % | |
T3 | 8 % | 9 % | 5 % | 5 % | 4 % | 9 % | 13 % | |
T4 | 1 % | 1 % | 1 % | 1 % | 1 % | 1 % | 1 % | |
Grade | (1) Well Differentiated | 11 % | 8 % | 3 % | 2 % | 2 % | 1 % | 1 % |
(2) Moderately Differentiated | 57 % | 58 % | 59 % | 55 % | 45 % | 41 % | 42 % | |
(3) Poorly Differentiated | 19 % | 23 % | 33 % | 40 % | 51 % | 54 % | 55 % | |
(4) Anaplastic | <1 % | <1 % | <1 % | <1 % | <1 % | 1 % | 1 % | |
Unknown | 13 % | 11 % | 5 % | 3 % | 2 % | 3 % | 1 % | |
High risk | T3-T4 or Grade 3–4 | 23 % | 29 % | 35 % | 42 % | 53 % | 59 % | 60 % |
Androgen deprivation | No | 68 % | 59 % | 53 % | 54 % | 54 % | 50 % | 59 % |
Therapy | Yes | 32 % | 41 % | 47 % | 46 % | 46 % | 50 % | 41 % |
Year treated | 1995–1997 | 54 % | 31 % | 5 % | 1 % | 1 % | 1 % | <1 % |
1998–2000 | 32 % | 40 % | 15 % | 5 % | 3 % | 3 % | <1 % | |
2001–2003 | 11 % | 19 % | 37 % | 30 % | 20 % | 14 % | 16 % | |
2004–2006 | 3 % | 10 % | 43 % | 64 % | 76 % | 82 % | 83 % | |
Medical | Cardiovascular Disease | 13 % | 19 % | 16 % | 15 % | 21 % | 25 % | 18 % |
Comorbidities | Diabetes mellitus | 5 % | 9 % | 4 % | 5 % | 8 % | 7 % | 7 % |
Respiratory Disease | 2 % | 3 % | 2 % | 2 % | 3 % | 5 % | 2 % |